VIVUS (VVUS) has been under a strong bear grip, hence the stock is down -1.22% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.25% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.87% in the last 1 week, and is up 5.45% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
VIVUS (NASDAQ:VVUS): The stock was completely flat for the day, closing at $1.16 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $1.15, the stock touched an intraday high of $1.18 and a low of $1.14. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.16. The total trading volume on Friday was 909,731.
The stock has recorded a 20-day Moving Average of 1.49% and the 50-Day Moving Average is 1.48%. VIVUS Inc. has dropped 35.56% during the last 3-month period . Year-to-Date the stock performance stands at 13.73%.
VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42,000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. As of September 18, 2014, the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.